Identification and development of synthetic lethal strategies and predictive biomarkers for therapy for MMR Deficient Co

鉴定和开发用于治疗 MMR 缺陷公司的合成致死策略和预测生物标志物

• 批准号: G0802325/1
• 负责人: Philippa Hewish
• 金额: $ 29.45万
• 依托单位: Institute of Cancer Research
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0802325%2F1
• 关键词: Identification; development; synthetic; lethal; strategies

We aim to identify and develop new ways of treating a particular type of large bowel cancer, caused by a defect in how DNA is repaired. At present, about 17% of cases of large bowel cancer have evidence of a deficiency in a DNA repair pathway called Mismatch Repair (MMR). This affects both young patients, who mainly have an inherited form of MMR deficiency, Lynch Syndrome, and older patients, who spontaneously develop a defect in one of the MMR genes. Using advanced molecular biology techniques to screen for potential drug targets, we aim to identify and develop those that could be of use in the clinical treatment of MMR deficient large bowel cancer, with the intention of taking them forwards into drug trials. The laboratory research will be based at the Institute of Cancer Research, and the clinical research at The Royal Marsden Hospital. In tandem with the development of new therapeutic strategies, we will also develop biomarkers. These are substances that can be tested in patient samples to predict whether they are likely to respond to a specific treatment or not.

我们的目标是识别和开发治疗特定类型大肠癌的新方法，这种癌症是由 DNA 修复缺陷引起的。目前，大约 17% 的大肠癌病例有证据表明 DNA 修复途径（称为错配修复 (MMR)）存在缺陷。这既影响年轻患者（主要患有遗传性 MMR 缺陷（林奇综合征）），也影响老年患者（其中一个 MMR 基因自发出现缺陷）。我们利用先进的分子生物学技术筛选潜在的药物靶点，旨在识别和开发可用于临床治疗 MMR 缺陷型大肠癌的靶点，并旨在将其推进药物试验。实验室研究将在癌症研究所进行，临床研究将在皇家马斯登医院进行。随着新治疗策略的开发，我们还将开发生物标志物。这些物质可以在患者样本中进行测试，以预测他们是否可能对特定治疗产生反应。